Ilaris

(canakinumab)

Phase 3Monoclonal antibody

Canakinumab is used to treat certain inflammatory conditions, including gout attacks and rare autoinflammatory diseases where the body's immune system causes excessive inflammation. It works by blocking a protein in the body that triggers inflammation.[1] Ilaris is currently being investigated across 11 indications[3], with its most advanced program in Phase 3.[1]

Ilaris is one of 304 small molecule programs targeting Rheumatic Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

303

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseRecruiting

Lung CancerTerminated

Muckle-Wells SyndromeUnknown

Immune System DiseaseUnknown

MyelofibrosisRecruiting

Contact DermatitisRecruiting

Chronic Myelomonocytic LeukemiaRecruiting

Pancreatic CancerRecruiting

Renal Cell CarcinomaActive, not recruiting

MDSActive, not recruiting

Rheumatic DiseasePhase 2

Recruiting

Lung CancerPhase 3

Terminated

Muckle-Wells SyndromePreclinical

Unknown

Immune System DiseasePreclinical

Unknown

MyelofibrosisPhase 2

Recruiting

Contact DermatitisPhase 3

Recruiting

Chronic Myelomonocytic LeukemiaPhase 2

Recruiting

Pancreatic CancerPhase 1

Recruiting

Renal Cell CarcinomaPhase 1

Active, not recruiting

MDSPhase 2

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

307 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Ilaris

Novartis

Phase 3

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Secretin-Ferring

Ferring

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

PD-1 Blocking Antibody

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Chronic Myelomonocytic Leukemia

NCT04239157

Q3 2027

Phase 2Recruiting

Myelofibrosis

NCT05467800

Q4 2027

Phase 2Recruiting

Lung Cancer

NCT04789681

Phase 2/3Recruiting

Contact Dermatitis

NCT05535738

Q1 2028

Phase 2Recruiting

Rheumatic Disease

NCT07138898

Clinical

Trials by Indication[1]

Efficacy and Safety6 trials

Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

Withdrawn· Novartis logo

Novartis·Phase 2·NCT02980263

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Completed· Novartis logo

Novartis·Phase 3·NCT02059291·203 enrolled

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Terminated· Novartis logo

Novartis·Phase 3·NCT03631199·673 enrolled

Show 3 more trials

Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

Completed· Novartis logo

Novartis·Phase 3·NCT02396212·19 enrolled

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Completed· Novartis logo

Novartis·Phase 2·NCT00819585·432 enrolled

Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

Completed· Novartis logo

Novartis·Phase 3·NCT04717635·14 enrolled

Systemic Juvenile Idiopathic Arthritis4 trials

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Completed· Novartis logo

Novartis·Phase 3·NCT02334748·31 enrolled

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Completed· Novartis logo

Novartis·Phase 3·NCT00889863·177 enrolled

An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Withdrawn· Novartis logo

Novartis·Phase 3·NCT01676948

Show 1 more trial

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.

Completed· Novartis logo

Novartis·Phase 3·NCT00891046·270 enrolled

Cryopyrin-Associated Periodic Syndrome3 trials

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Completed· Novartis logo

Novartis·Phase 3·NCT00685373·166 enrolled

Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

Completed· Novartis logo

Novartis·Phase 3·NCT00991146·19 enrolled

The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

Completed· Novartis logo

Novartis·Phase 3·NCT01105507·4 enrolled

Rheumatoid Arthritis3 trials

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

Completed· Novartis logo

Novartis·Phase 2·NCT00424346·274 enrolled

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

Completed· Novartis logo

Novartis·Phase 2·NCT00487825·78 enrolled

Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis

Completed· Novartis logo

Novartis·Phase 2·NCT00554606·115 enrolled

Non-Small Cell Lung Cancer3 trials

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Terminated· Novartis logo

Novartis·Phase 3·NCT03447769·1,382 enrolled

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

Terminated· Novartis logo

Novartis·Phase 3·NCT03626545·245 enrolled

Phase I/II Study of Canakinumab With Chemoradiation and Durvalumab for Unresected Locally-Advanced Non-Small Cell Lung Cancer (CHORUS)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04905316·41 enrolled

51 more indications

Arthritis2 trials

Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Completed· Novartis logo

Novartis·Phase 3·NCT01431638·397 enrolled

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Completed· Novartis logo

Novartis·Phase 3·NCT01356602·397 enrolled

Lung Cancer2 trials

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04789681·50 enrolled

A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer

Terminated· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 3·NCT05725343·350 enrolled

Cardiovascular2 trials

Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

Completed·PPriscilla Hsue, MD·Phase 2·NCT02272946·43 enrolled

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Completed· Novartis logo

Novartis·Phase 3·NCT01327846·10,066 enrolled

Osteoarthritis2 trials

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

Terminated· Novartis logo

Novartis·Phase 2·NCT04814368·23 enrolled

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

Completed· Novartis logo

Novartis·Phase 2·NCT01160822·169 enrolled

Type 2 Diabetes2 trials

Canakinumab in Patients With COVID-19 and Type 2 Diabetes

Completed·UUniversity Hospital, Basel, Switzerland·Phase 3·NCT04510493·116 enrolled

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

Completed· Novartis logo

Novartis·Phase 2·NCT00605475·231 enrolled

Familial Mediterranean Fever2 trials

Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever

Completed· Novartis logo

Novartis·Phase 2·NCT01088880·10 enrolled

Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)

Completed· Novartis logo

Novartis·Phase 2·NCT01148797·15 enrolled

Pneumonia2 trials

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia

Completed· Novartis logo

Novartis·Phase 3·NCT04362813·454 enrolled

Canakinumab MAP in COVID-19 Pneumonia With CRS

No longer available· Novartis logo

Novartis··NCT04476706

Non-steroidal Anti-inflammatory Drugs2 trials

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study

Completed· Novartis logo

Novartis·Phase 3·NCT01029652·230 enrolled

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

Completed· Novartis logo

Novartis·Phase 3·NCT01080131·226 enrolled

COVID-192 trials

Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

Completed·TThe Cleveland Clinic·Phase 2·NCT04365153·45 enrolled

COVID-19 VaccinE Response in Rheumatology Patients

Completed·JJeffrey Curtis·Phase 4·NCT05080218·841 enrolled

Schnitzler syndrome2 trials

Efficacy and Safety of Canakinumab in Schnitzler Syndrome

Completed·RRadboud University Medical Center·Phase 2·NCT01276522·8 enrolled

Ilaris® Effects in Schnitzler Syndrome (ILESCH)

Completed·—·Phase 2·NCT01390350·20 enrolled

Adult-Onset Still's Disease1 trial

Canakinumab for Treatment of Adult-onset Still's Disease

Terminated·—·Phase 2·NCT02204293·36 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

Completed· Novartis logo

Novartis·Phase 1/2·NCT00581945·147 enrolled

Intravenous Administration1 trial

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

Completed· Novartis logo

Novartis·Phase 2·NCT01250171·72 enrolled

Chronic Myelomonocytic Leukemia1 trial

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04239157·76 enrolled

Hypoglycemia1 trial

Canakinumab for the Treatment of Postprandial Hypoglycemia

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 3·NCT05401578·56 enrolled

Cognitive impairment1 trial

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

Terminated· Novartis logo

Novartis·Phase 2·NCT04795466·34 enrolled

Adjuvant Treatment1 trial

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Terminated· Novartis logo

Novartis·Phase 2·NCT03968419·88 enrolled

Efficacy1 trial

Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms

Completed· Novartis logo

Novartis·Phase 2·NCT00487708·34 enrolled

Pyoderma Gangrenosum1 trial

Canakinumab for Pyoderma Gangrenosum

Completed·UUniversity of Zurich·Phase 2·NCT01302795·5 enrolled

Renal Cell Carcinoma1 trial

A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma

Active, not recruiting·—·Phase 1·NCT04028245·17 enrolled

Prevention1 trial

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Recruiting·UUma Borate·Phase 2·NCT05641831·110 enrolled

Metastatic NSCLC1 trial

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Terminated· Novartis logo

Novartis·Phase 1·NCT03064854·111 enrolled

Refractory1 trial

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Completed· Novartis logo

Novartis·Phase 2·NCT00798369·200 enrolled

Gout1 trial

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Completed· Novartis logo

Novartis·Phase 2·NCT00927810·341 enrolled

Breast Cancer1 trial

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Terminated· Novartis logo

Novartis·Phase 1·NCT03742349·64 enrolled

Myelofibrosis1 trial

Study of Canakinumab in Patients With Myelofibrosis

Recruiting·JJohn Mascarenhas·Phase 2·NCT05467800·14 enrolled

Type 1 Diabetes1 trial

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00947427·71 enrolled

Peripheral Artery Disease1 trial

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

Terminated· Novartis logo

Novartis·Phase 2·NCT01731990·38 enrolled

Colchicine1 trial

Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective

Terminated· Novartis logo

Novartis·Phase 3·NCT01362608·136 enrolled

Impaired glucose tolerance1 trial

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Completed· Novartis logo

Novartis·Phase 2·NCT01068860·246 enrolled

Periodic Fever Syndrome1 trial

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

Completed· Novartis logo

Novartis·Phase 3·NCT02911857·4 enrolled

MDS1 trial

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT04798339·13 enrolled

Duchenne Muscular Dystrophy1 trial

Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy

Unknown status·—·Phase 1/2·NCT03936894·3 enrolled

Proliferative Diabetic Retinopathy1 trial

A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)

Terminated·PPD Dr. med. Stephan Michels·Phase 1·NCT01589029·6 enrolled

Anemia1 trial

Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

Terminated·UUniversity of Leipzig·Phase 2·NCT05237713·10 enrolled

Juvenile Idiopathic Arthritis1 trial

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

Terminated· Novartis logo

Novartis·Phase 3·NCT00886769·84 enrolled

Hospitalized Patients1 trial

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

Completed· Novartis logo

Novartis·Phase 2·NCT00663169·6 enrolled

Inflammatory Disease1 trial

Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

Terminated· Novartis logo

Novartis·Phase 3·NCT00770601·7 enrolled

Contact Dermatitis1 trial

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Recruiting·WWei-Che Ko·Phase 2/3·NCT05535738·45 enrolled

Pancreatic Cancer1 trial

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Recruiting·NNYU Langone Health·Phase 1·NCT05984602·10 enrolled

Vasculitis1 trial

Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses

Completed·—·Phase 2·NCT01170936·10 enrolled

Pharyngitis1 trial

Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)

Unknown status·RRabin Medical Center·Phase 1·NCT02775994·10 enrolled

Cardioversion1 trial

Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF

Terminated·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT01805960·24 enrolled

Phase IB1 trial

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Terminated· Novartis logo

Novartis·Phase 1·NCT04810611·33 enrolled

Type 2 Diabetic Patients1 trial

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

Terminated· Novartis logo

Novartis·Phase 2/3·NCT00900146·556 enrolled

Urticaria1 trial

Efficacy Study of Canakinumab to Treat Urticaria

Unknown status·UUniversity of Zurich·Phase 2·NCT01635127·20 enrolled

Treatment1 trial

1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement

Completed· Novartis logo

Novartis·Phase 2·NCT02756650·8 enrolled

Vascular Inflammation1 trial

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

Recruiting·MMassachusetts General Hospital·Phase 2·NCT06691217·120 enrolled

Rheumatic Disease1 trial

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Recruiting·NNYU Langone Health·Phase 2·NCT07138898·80 enrolled

Cigarette Smoking-Related Carcinoma1 trial

Molecular Studies of Canakinumab in High-Risk Former-Smokers (CANIFS)

Completed·PPeter Shields·Phase 2·NCT06038526·41 enrolled

Unspecified1 trial

Canakinumab in Patients With Active Hyper-IgD Syndrome

Completed· Novartis logo

Novartis·Phase 2·NCT01303380·9 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 17, 2009

ILARIS

BLA BLA125319

Jun 17, 2009

ILARIS

NDA BLA125319

Nov 17, 2011

ILARIS

NDA BLA125319

Mar 30, 2012

ILARIS

NDA BLA125319

Oct 11, 2012

ILARIS

NDA BLA125319

May 9, 2013

ILARIS

NDA BLA125319

Oct 16, 2014

ILARIS

NDA BLA125319

Jul 21, 2016

ILARIS

NDA BLA125319

Sep 23, 2016

ILARIS

NDA BLA125319

Sep 23, 2016

ILARIS

NDA BLA125319

Sep 23, 2016

ILARIS

NDA BLA125319

Dec 22, 2016

ILARIS

NDA BLA125319

Jun 16, 2020

ILARIS

NDA BLA125319

Sep 18, 2020

ILARIS

NDA BLA125319

Aug 25, 2023

ILARIS

NDA BLA125319

Nov 1, 2024

ILARIS

NDA BLA125319

Sources

References

[1]
ClinicalTrials.gov — 80 trial records for canakinumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — canakinumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for canakinumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA BLA125319). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Interleukin-1 Beta Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Novartis

Ilaris

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Efficacy and Safety6 trials

Systemic Juvenile Idiopathic Arthritis4 trials

Cryopyrin-Associated Periodic Syndrome3 trials

Rheumatoid Arthritis3 trials

Non-Small Cell Lung Cancer3 trials

Arthritis2 trials

Lung Cancer2 trials

Cardiovascular2 trials

Osteoarthritis2 trials

Type 2 Diabetes2 trials

Familial Mediterranean Fever2 trials

Pneumonia2 trials

Non-steroidal Anti-inflammatory Drugs2 trials

COVID-192 trials

Schnitzler syndrome2 trials

Adult-Onset Still's Disease1 trial

Chronic Obstructive Pulmonary Disease1 trial

Intravenous Administration1 trial

Chronic Myelomonocytic Leukemia1 trial

Hypoglycemia1 trial

Cognitive impairment1 trial

Adjuvant Treatment1 trial

Efficacy1 trial

Pyoderma Gangrenosum1 trial

Renal Cell Carcinoma1 trial

Prevention1 trial

Metastatic NSCLC1 trial

Refractory1 trial

Gout1 trial

Breast Cancer1 trial

Myelofibrosis1 trial

Type 1 Diabetes1 trial

Peripheral Artery Disease1 trial

Colchicine1 trial

Impaired glucose tolerance1 trial

Periodic Fever Syndrome1 trial

MDS1 trial

Duchenne Muscular Dystrophy1 trial

Proliferative Diabetic Retinopathy1 trial

Anemia1 trial

Juvenile Idiopathic Arthritis1 trial

Hospitalized Patients1 trial

Inflammatory Disease1 trial

Contact Dermatitis1 trial

Pancreatic Cancer1 trial

Vasculitis1 trial

Pharyngitis1 trial

Cardioversion1 trial

Phase IB1 trial

Type 2 Diabetic Patients1 trial

Urticaria1 trial

Treatment1 trial

Vascular Inflammation1 trial

Rheumatic Disease1 trial

Cigarette Smoking-Related Carcinoma1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News